The Citadel Group Ltd (ASX: CGL) share price rose by nearly 4% after giving investors an update regarding a health contract.
In January 2018 Citadel let the market know that Queensland Health intended to adopt a competing laboratory information system (LIS) in place of Citadel's Auslab system.
Citadel announced today that it has signed an extension for Auslab to continue to operate for Queensland Health to 2029, "pending the succesful delivery of the competing solution."
As part of the extension, Citadel will continue to provide Auslab until at least 1 January 2023, and will also deliver an update to Auslab Evolution, so that Queensland Health will have the best Citadel offering.
Managing Director Mark McConnell said: "We are very proud of our history with Queensland Health, and this extension provides one of our longest-standing clients with security of service, and an opportunity to see the benefits of our latest feature-rich enterprise laboratory software."
Citadel's share price is down 44% over the past year, but it's up 40% since the end of October 2019.
